Novavax NASDAQ: NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
Name | Novavax |
Ticker | NVAX |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Clinical trial work |
Price
52W Low/High |
202.09
17.14 / 319.93 |
Momentum | Neutral |
Market cap | 13 B |
1Y Total Return |
1,016.52%
Strong |
1Y Volatility |
130.31%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
Details
Ticker | NVAX |
Name | Novavax |
ISIN | US6700024010 |
CUSIP | 670002401 |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Clinical trial work |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/15/21
Close Price | 202.09 |
52W Low/High | 17.14 / 319.93 |
Market cap | 13 B |
1Y Total Return |
1,016.52%
Strong |
1Y Volatility |
130.31%
High Risk |
Beta | 0.45 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -87.9% |
Cash from Op. / Cur. Liabilities | -0.07 |
Diluted Earnings / Share | -7.27 |
ROE | - |
ROIC | -192.4% |
Price / Revenue | 24.5 |
Price / Book | 18.5 |
Price / CF | -273.4 |
Current Ratio | 2.2 |
Cur.Liabilities / Tot.Liabilities | 0.6 |
Financial Leverage | 0.75 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
476
|
19
|
34
|
31
|
15
|
36
|
|
Gross Profit |
476
|
19
|
34
|
31
|
15
|
36
|
|
R&D |
747
|
114
|
174
|
168
|
238
|
163
|
|
EBITDA |
-152
|
-113
|
-163
|
-160
|
-258
|
-151
|
|
Operating Income |
-417
|
-121
|
-174
|
-172
|
-269
|
-157
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
58
|
24
|
18
|
15
|
14
|
13
|
|
EPS exc. Extra |
-7.27
|
-5.51
|
-9.99
|
-12.56
|
-20.60
|
-12.00
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
1,582
|
173
|
208
|
302
|
394
|
386
|
|
Cash, Eq & Invt ShortTerm |
806
|
82
|
104
|
186
|
270
|
268
|
|
Total Current Assets |
1,248
|
97
|
119
|
203
|
288
|
287
|
|
Total Non-Current Assets |
334
|
76
|
89
|
99
|
106
|
99
|
|
Intangibles |
141
|
57
|
59
|
61
|
61
|
64
|
|
Total Liabilities |
955
|
359
|
376
|
404
|
400
|
93
|
|
Total Current Liabilities |
580
|
26
|
46
|
74
|
66
|
76
|
|
Long Term Debt |
376
|
333
|
330
|
331
|
333
|
17
|
|
Shareholder equity |
627
|
-186
|
-168
|
-102
|
-6
|
293
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-43
|
-137
|
-185
|
-144
|
-259
|
-126
|
|
Depreciation |
251
|
6
|
8
|
10
|
9
|
6
|
|
Cash from Investing |
-378
|
38
|
29
|
36
|
28
|
-21
|
|
Capex |
55
|
16
|
1
|
4
|
18
|
18
|
|
Cash from Financing |
985
|
98
|
103
|
65
|
280
|
208
|
|
Stock Issued |
920
|
98
|
103
|
65
|
4
|
209
|
|
Debt (LT) Issued |
-96
|
0
|
0
|
0
|
325
|
-1
|
|
Free Cash Flow |
1
|
-132
|
-164
|
-120
|
-234
|
-121
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
2.2
|
3.8
|
2.6
|
2.8
|
4.3
|
3.8
|
|
Financial Leverage D/E |
0.75
|
-
|
-
|
-
|
-
|
0.00
|
|
Return on Capital Avg |
-192.4%
|
-163.7%
|
-196.9%
|
-140.2%
|
-163.0%
|
-80.7%
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available